Reduction in urinary protein loss in kidney disease(Ig A Nephropathy)with Finerenone plus telmisartan when compared to Telmisartan alone

TO EVALUATE THE COMBINED EFFECT OF FINERENONE WITH TELMISARTAN IN COMPARISON TO TELMISARTAN MONOTHERAPY ON URINARY PROTEIN CREATININE RATIO (UPCR) IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN) - A RANDOMIZED PROSPECTIVE OPEN LABEL STUDY - CPT/FIN/01

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/04/108814

Enrollment

Registered

2026-04-20

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N063- Isolated proteinuria with diffusemesangial proliferative glomerulonephritis

Interventions

Intervention1: TABLET FINERENONE: TABLET FINERENONE 10 MG ONCE DAILY FOR 3 MONTHS Control Intervention1: TABLET TELMISARTAN: TABLET TELMISARTAN 40 MG TO 80 MG ONCE DAILY FOR 3 MONTHS

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged between 18-65 years and both genders will be included in the study Biopsy proven denovo cases of IgA nephropathy Urinary protein creatinine ratio greater than or equal to 0.5 Estimated glomerular filtration rate (eGFR) of greater than or equal 25 mL/min/1.73m Serum potassium less than or equal 4.8 mmol/L at baseline Willingness to provide written informed consent

Exclusion criteria

Exclusion criteria: Other glomerular diseases like non IgA Glomerulonephritis, tubulo interstitial nephritis Patient with hepatic disease: ALT or AST greater than 3 times the upper limit of normal, total bilirubin greater than 2 mg/dL, or clinical evidence of hepatic dysfunction (example includes jaundice, ascites). Known hypersensitivity or allergy to either of the study drug Treatment with immunosuppressants or glucocorticoids Participants who had any organ Transplantation Women who are pregnant, breastfeeding or planning pregnancy during the study period. Participants diagnosed with Diabetes Mellitus Critically ill patients

Design outcomes

Primary

Measure	Time frame
Mean change in Urinary Protein Creatinine Ratio in both groups from baseline to end of studyTimepoint: Baseline End of 1 Month and End of 3 months in both the study groups	—

Secondary

Measure	Time frame
Change in eGFR (CKD-EPI formula) from baseline to end of 3 months in both the study groups Change in serum albumin from baseline to end of 3 months in both the study groups Change in serum potassium from baseline to end of 3 months in both the study groups Incidence of Adverse events in both groups during study period Timepoint: Baseline End of 1 Month and End of 3 Months	—

Countries

India

Contacts

Public ContactDR D SUJAT KUMAR

NIZAMS INSTITUTE OF MEDICAL SCIENCES

thippana.padmaja@gmail.com9100953423

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026